Treatment of SHR6390 suppressed cell proliferation and tumor growth in ESCC cell lines and xenografts by inhibiting levels of pRb and effectively arrested the cell cycle at the G1 phase with the expression levels of p53 and p21 were upregulated. This evidence concerns the gene RB1 and neoplasm.